Daily non-political popular news in brief.
Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
05-16-2007 · EurekAlert!Clinical trial data for Perforomist Inhalation Solution will be presented at ATS on May 20, 2007. Data from Phase III pivotal trial demonstrates safety and efficacy of first FDA-approved nebulized formoterol fumarate for patients with moderate to severe COPD.
Read more »
Keywords: clinical, trial, data, perforomist, inhalation, solution, presented, ats, 2007
« Previous | Next »
Similar news on "Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007":
- Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
05-21-2007 · EurekAlert!
New product recently approved by FDA for long-term maintenance treatment of COPD bronchoconstriction; data demonstrate first nebulized formoterol fumarate provides improved lung function comparable to dry powder formoterol, enhanced patient quality of life, and positive safety profile.
Similar news · Read more »
- Clinical trials nebulized formoterol fumarate: Long-term and cardiovascular safety COPD
10-24-2007 · EurekAlert!
Data from two Phase III clinical trials were presented today in Chicago at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians, supporting the use of Perforomist Inhalation Solution as a safe and effective maintenance treatment for COPD patients.
Similar news · Read more »
- Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
10-24-2007 · EurekAlert!
Data presented today at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians, demonstrate concomitant use of nebulized formoterol fumarate and tiotropium provided improved bronchodilation over tiotropium monotherapy and was well-tolerated in this clinical study.
Similar news · Read more »
- HORIZONS AMI trial data will help set guidelines
10-24-2007 · EurekAlert!
Late-breaking data presented at TCT 2007, the scientific symposium of the Cardiovascular Research Foundation, show that the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduces net adverse clinical events by 24 percent compared to the standard treatment, and significantly reduces major bleeding that occurs after angioplasty by 40 percent.
Similar news · Read more »
- Infants with bronchiolitis may benefit more from albuterol
05-16-2007 · EurekAlert!
Bronchiolitis, a wheezing much like asthma in adults, is responsible for many hospital admissions of infants. There are two drugs in general use to treat this condition, epinephrine and albuterol, and there is some controversy and passion involved in the choice of medication. In a paper to be presented at the 2007 Society for Academic Emergency Medicine Annual Meeting, a double-blind randomized clinical trial involving over 700 infants showed a clear advantage for albuterol.
Similar news · Read more »
- Results of world's first fully bioabsorable coronary artery stent clinical trial
03-24-2007 · EurekAlert!
Late breaking data presented at the American College of Cardiology Meeting shows positive results for world's first fully bioabsorbable coronary artery stent clinical trial.
Similar news · Read more »
- New data show ACTOS(r) (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
11-13-2006 · EurekAlert!
Researchers today presented data showing that ACTOS® (pioglitazone HCl) halted the progression of atherosclerosis as measured by carotid intima-media thickness (CIMT) in patients with type 2 diabetes. Results from the clinical trial, CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne), are part of a late-breaker presentation at the American Heart Association's Scientific Sessions 2006, coincidentally being held in Chicago, and coincide with an early online issue of the Journal of the American Medical Association.
Similar news · Read more »
- New data show ACTOS (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
11-13-2006 · EurekAlert!
Researchers today presented data showing that ACTOS (pioglitazone HCl) halted the progression of atherosclerosis as measured by carotid intima-media thickness (CIMT) in patients with type 2 diabetes. Results from the clinical trial, CHICAGO (Carotid intima-media thickness in Atherosclerosis using pioglitazone), are part of a late-breaker presentation at the American Heart Association's Scientific Sessions 2006, coincidentally being held in Chicago, and coincide with an early online issue of the Journal of the American Medical Association.
Similar news · Read more »
- Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
10-23-2006 · EurekAlert!
Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
Similar news · Read more »
- Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years
11-13-2006 · EurekAlert!
Amgen (NASDAQ: AMGN) announced patients with ankylosing spondylitis who received treatment with Enbrel (R) (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy, according to data from an ongoing open-label, multinational, phase 4 extension study presented at the American College of Rheumatology scientific meeting. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks.
Similar news · Read more »
